Finanzas de Dyne Therapeutics, Inc (DYN)DYNDyne Therapeutics, Inc

Evaluating the bottom line, Dyne Therapeutics, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -81.57%, provide a clear picture of how effectively DYN converts its operational activities into shareholder value.

In the context of the broader market, DYN competes directly with industry leaders such as RCUS and DNLI. With a market capitalization of $2.66B, it holds a significant position in the sector. When comparing efficiency, DYN's gross margin of N/A stands against RCUS's 100.00% and DNLI's 76.61%. Such benchmarking helps identify whether Dyne Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Dyne Therapeutics has reported consistent losses, with a net income of -178,556,000 USD in Q2 2026 and a negative EPS of -1.08, indicating poor financial health.